Beleggen.nl
Uitgebreid zoeken
Markt MonitorMarkt Monitor

BioPharma Terug naar discussie overzicht

HIV; waarom lager?

1.470 Posts
Pagina: «« 1 ... 66 67 68 69 70 ... 74 »» | Laatste | Omlaag ↓
  1. [verwijderd] 6 februari 2008 16:57

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Laatste 0,1500 16:46 5.000
    +/- 0,0200 15,38%
    Slot 0,1300 05-02-08
    Open 0,1300 15:31
    Hoog 0,1500 16:27
    Laag 0,1200 15:32
    Bied
    Laat
    Volume 218.870

    voorlopig weer 15,38 %.

    vr gr willem
  7. [verwijderd] 11 februari 2008 13:22

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    fox1405 schreef:

    Sec filing gezien, maar wat houdt deze nu in begrijpelijk Nederlands in? Ik kan er niet zo goed wijs uit worden.

    Fox
    Ik heb dit gvonden op Ihub

    4/25/06: SEC to issue effectiveness order electronically

    At long last, the SEC has announced that it will issue effectiveness orders on registration statements electronically, rather than mailing the orders as is currently the SEC's practice, often several months after the fact. On May 22, 2006, the staffs of the Divisions of Corporation Finance and Investment Management will begin to use the EDGAR system to issue notifications of effectiveness for Securities Act registration statements and post-effective amendments, other than those that become effective automatically by law (e.g., WKSI s-3S, all S-8s et al). These notifications will be posted to the EDGAR system the morning after a filing is determined to be effective. The Divisions will no longer prepare and mail paper effectiveness orders associated with these filings. Registrants will continue to be notified promptly by telephone that their registration statements or post-effective amendments are effective. After May 22, 2006, the SEC's website will also present a list of filings declared effective on the previous business day. The effectiveness notices will be distributed as an EDGAR form type called "EFFECT." The public will now be able to search for a company's filings and be able to see when the staff declared a particular Securities Act registration statement effective.

    www.sandw.com/f-3.html
  10. [verwijderd] 1 april 2008 20:56

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Tsja, wat zullen we er van zeggen. Ik begin het geloof een beetje kwijt te raken. Koers inmiddels op 7 dollarcent terug. Verkopen zijn nihil en het hele China verhaal begint op gebakken lucht te lijken. Ik geef ze nog tot 1 mei, anders stap ik eruit.

    Fox
  13. [verwijderd] 4 april 2008 20:11

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Zijn de zakken van de geldschieters stillaan gevuld ? Ik denk dat er binnenkort nieuws kan komen. Er is nog al wat steun op 0.06/0.05 en naar boven toe is het boekje vrij dun. Net of ze hem bij nieuws snel willen laten doorschieten naar 0.25
  15. [verwijderd] 15 april 2008 13:05

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    PROSPECTUS

    CALYPTE BIOMEDICAL CORPORATION

    54,000,000 Shares of Common Stock

    • This prospectus relates to the sale of up to 54,000,000 shares of our common stock by Fusion Capital Fund II, LLC. We will not receive any proceeds from the sale of our shares in this offering.

    • Our common stock is registered under Section 12(g) of the Securities Exchange Act of 1934, as amended, and quoted on the Nasdaq Over-the-Counter Bulletin Board under the symbol "CBMC." On April 11, 2008, the last reported sale price for our common stock as reported on the Nasdaq Over-the-Counter Bulletin Board was $0.069 per share.

    Het ziet er dus niet naar uit, dat er snel een deal zal zijn.

    P.
  16. [verwijderd] 16 april 2008 21:13

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Deal??

    China??

    Calypte Biomedical Corp. has added a news release to its Investor Relations website.

    Title: Calypte Biomedical Corporation to Host Conference Call on April 17, 2008 to Discuss Significant International Development
    Date: 4/16/2008 3:05:01 PM

    For a complete listing of our news releases, please click here

    P.
  18. [verwijderd] 17 april 2008 14:12

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    CHINA DUS!!!!!!!!!!

    ---OnlyOnlyOnlyOnly---

    Calypte's Aware(TM) HIV-1/2 OMT Approved as China's Only Rapid Oral HIV Test

    Approval Enables Manufacturing, Marketing, Distribution and Sales throughout China

    Company to Hold Conference Call at 10:30 a.m. EDT Today to Discuss Developments

    PORTLAND, Ore.--(BUSINESS WIRE)--April 17, 2008--

    Calypte Biomedical Corporation (OTCBB:CBMC), a developer, manufacturer and marketer of HIV diagnostic tests, announced today that its Chinese subsidiary, Beijing Marr Bio-Pharmaceutical Co. Ltd. ("Beijing Marr"), has received registration and marketing approval for Calypte's Aware(TM) HIV-1/2 OMT (oral fluid) rapid test from the State Food and Drug Administration ("SFDA") of China. This approval makes the Aware(TM) HIV-1/2 OMT test the first and only SFDA approved rapid oral fluid HIV test in China.

    Roger Gale, Calypte's Chairman and Chief Executive Officer, stated, "This is a major accomplishment for Calypte and we are thrilled to have received this long awaited approval which permits us to begin actively marketing our rapid diagnostic tests in China, one of the potentially largest HIV testing markets in the world. With the medical devices manufacturing permit received earlier this year, our Beijing Marr subsidiary is now able to manufacture, market, distribute and sell the Aware(TM) HIV-1/2 OMT test throughout the Peoples' Republic of China. China is committed to aggressively tackle the spread of its HIV epidemic and we believe that our Aware(TM) HIV-1/2 OMT (oral fluid) test can and will make a significant contribution to that effort. We appreciate the patience of those investors who have supported us through the long SFDA approval process, particularly our joint venture partners, the Marr Group." Mr. Gale added, "This approval also gives us, for the first time, a very valuable approval in the country of manufacture. Absence of this approval in the past has hampered our ability to register and market the test in a number of countries, a hurdle we can now overcome by producing the domestically approved Aware(TM) product in our Chinese factory. With this SFDA approval, we are now in a position to market and sell in countries representing a total population of nearly 3.7 billion, or over half of the worlds' population."

    Dr. Ronald Mink, Chief Science Officer for Calypte, remarked, "This approval has validated our perseverance in pursuing the registration of a product in which we have long had confidence. The transformation of the SFDA over the past two to three years into a first tier agency matching the rigor and integrity of its U.S. and European counterparts resulted in a very thorough review of the Aware(TM) HIV-1/2 OMT (oral fluid) test. We believe that the Chinese authorities are now comfortable with this new technology, which expands the scope of testing platforms currently available in China. The SFDA's restructuring has resulted in a review process and timetable that is similar to what we see in the U.S. FDA. We believe these changes will benefit not only China, by setting a higher standard for new medical products, but will also benefit us, by setting a higher barrier to market entry for would-be competitors. Throughout the entire review process, we received continually positive feedback from the SFDA and we have been confident that our technology is solid and our registration would prevail."

    David Harris, Beijing Marr's Chief Executive Officer, stated, "This is a very exciting moment for those of us at Beijing Marr who have worked very hard to gain this approval and ready the factory for manufacture, sale and distribution of the Aware(TM) HIV-1/2 OMT test. We have already received numerous inquiries from HIV program managers and scientists eager to use the product here in China. We now plan to ramp up our production capacity as we build our distribution network to fully realize the market potential of the Aware(TM) HIV-1/2 OMT test in China. Beijing Marr is committed to, and enthusiastic about, bringing this exciting new technology to the Chinese medical community."

    Calypte operates in China through Beijing Marr, a joint venture between Calypte and the Marr Group established to manufacture Calypte's Aware(TM) line of rapid HIV tests, including the Aware(TM) HIV-1/2 OMT product for both the Chinese and international markets. Beijing Marr operates an ISO 13485:2003 certified manufacturing facility on the outskirts of Beijing. The Aware(TM) HIV-1/2 OMT product is a rapid test using oral fluid to diagnose HIV-1 or HIV-2 infection in as little as 20 minutes with an accuracy comparable to that of U.S. FDA approved blood based laboratory HIV EIA tests.

    Conference Call:

    Calypte will host a conference call today at 10:30 a.m. EDT. The call can be accessed in the U.S. by dialing 866-510-0707 and outside of the U.S. by dialing 617-597-5376. The participant pass code is 49798845. The conference call will also be webcast live at www.calypte.com. An audio replay of the call will be available through May 18, 2008, beginning approximately 1 hour after the conference call ends, by dialing 888-286-8010 in the U.S., or 617-801-6888 from outside of the U.S. The pass code for the playback is 64031187. The web cast will also be available for replay on Calypte's website.


  20. [verwijderd] 17 april 2008 17:15

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    ajason schreef:

    de stijging is minder als menigeen hier had verwacht.
    Ach, +40% bij 4,5 milj. aandelen tot nu toe ipv 300.000 per dag.
    Volume procedes price!!!!!!!

    P.
1.470 Posts
Pagina: «« 1 ... 66 67 68 69 70 ... 74 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beleggen.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.001
AB InBev 2 5.481
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.194
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 264
Accsys Technologies 23 10.501
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 188
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.647
Aedifica 3 901
Aegon 3.258 322.648
AFC Ajax 538 7.086
Affimed NV 2 6.287
ageas 5.844 109.885
Agfa-Gevaert 14 2.048
Ahold 3.538 74.292
Air France - KLM 1.025 34.991
AIRBUS 1 11
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.035
Alfen 16 24.319
Allfunds Group 4 1.468
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 405
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.812
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.835 242.709
AMG 971 133.042
AMS 3 73
Amsterdam Commodities 305 6.686
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 482
Antonov 22.632 153.605
Aperam 92 14.902
Apollo Alternative Assets 1 17
Apple 5 380
Arcadis 252 8.731
Arcelor Mittal 2.033 320.556
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.288
Aroundtown SA 1 219
Arrowhead Research 5 9.715
Ascencio 1 26
ASIT biotech 2 697
ASMI 4.108 39.078
ASML 1.766 105.977
ASR Nederland 21 4.451
ATAI Life Sciences 1 7
Atenor Group 1 469
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.609
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.390